BullFrog AI Announces Three-Year Global Strategic Partnership with the Lieber Institute for Brain Development
September 13 2023 - 7:01AM
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or
the "Company"), a technology-enabled drug development company using
artificial intelligence (AI) and machine learning to enable the
successful development of pharmaceuticals and biologics, today
announced a three-year global strategic partnership with the
Lieber Institute for Brain Development (LIBD), a non-profit
research institute that maintains the world's largest repository of
postmortem brains for the study of neuropsychiatric disorders.
Under the terms of the agreement, BullFrog AI
will leverage its bfLEAP™ platform to mine LIBD's comprehensive
brain data, including transcriptomic, genomic, DNA methylation,
cell-line, clinical, and imaging data. The goal of the partnership
is to identify previously unrecognized relationships between genes
and pathways in the brain and the development of neurologic and
psychiatric disorders, thereby facilitating the development of more
effective treatments for diseases of the human brain. The
collaboration will proceed in two stages, with the first involving
unsupervised construction of graphical models to reveal
relationships between brain diseases and genomic/biologic
attributes, with the goal of identifying new biomarkers and drug
targets across disorders. The second stage will involve creating
disease-specific models that will enable identification of genes
and pathways within these respective disorders.
“This first of its kind global partnership with
LIBD represents a significant advancement in using AI to drive
precision medicine and will leverage BullFrog AI's bfLEAP™
artificial intelligence platform to accelerate research and
development initiatives, including drug repurposing, clinical trial
optimization, and drug target identification," said Vin Singh, CEO
of BullFrog AI. "Access to best-in-class data is a critical first
step in harnessing AI to improve drug development. Combining our
proprietary bfLEAP™ artificial intelligence platform with LIBD’s
extensive brain-related data positions us to accelerate the
development of therapies for psychiatric and neurologic
disorders.”
The partnership includes a one-year term of data
exclusivity to complete the first stages of analyses, with a
two-year extension option as performance milestones are met.
Throughout the collaboration, BullFrog AI will receive access to
LIBD’s collection of brain data for further analyses and additional
research projects. BullFrog AI will also have the right to
commercialize any product or service generated from the data. The
agreement specifies sharing of revenue between BullFrog AI and LIBD
from products or services generated from the partnership.
"This partnership enables us to apply BullFrog
AI’s innovative AI platform to rapidly accelerate our research and
development initiatives,” said Daniel R. Weinberger, M.D., Director
and CEO of LIBD. “We strongly believe this collaboration will
advance our understanding of brain disorders and ultimately lead to
new and better treatments for psychiatric and neurologic
diseases."
About the Lieber Institute for Brain
Development (LIBD)The mission of the Lieber Institute
for Brain Development and the Maltz Research Laboratories is
to translate the understanding of basic genetic and molecular
mechanisms of schizophrenia and related developmental brain
disorders into clinical advances that change the lives of affected
individuals. LIBD is an independent, not-for-profit 501(c)(3)
organization and a Maryland tax-exempt medical research institute.
The Lieber Institute’s brain repository of more than 4,000 human
brains is the largest collection of postmortem brains for the study
of neuropsychiatric disorders in the world.
About BullFrog AIBullFrog AI is
a technology-enabled drug development company that creates and
analyzes networks of biological, clinical, and real-world data
spanning from early discovery to late-stage clinical trials.
Through its partnerships with leading research institutions,
BullFrog AI is at the forefront of AI-driven drug development using
its proprietary bfLEAP™ artificial intelligence platform. BullFrog
AI is deploying bfLEAP™ for use at several critical stages of
development with the intention of streamlining data analytics in
therapeutics development, decreasing the overall development costs
by decreasing failure rates for new therapeutics.
For more information visit BullFrog AI
atWebsite: https://bullfrogai.com LinkedIn:
https://www.linkedin.com/company/bullfrogai/
Safe Harbor StatementThis press
release contains forward-looking statements. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. We are not obligated to
publicly update or revise any forward-looking statement, whether as
a result of uncertainties and assumptions, the forward-looking
events discussed in this press release and other statements made
from time to time by us or our representatives might not occur.
BFRGContact:InvestorsDave
GentryRedChip Companies, Inc.BFRG@redchip.com800-733-2447
MediaTiberend Strategic Advisors, Inc.Eric
Reissereiss@tiberend.com802-249-1136
Dave
Schemeliadschemelia@tiberend.com609-468-9325
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jul 2023 to Jul 2024